NASDAQ:KNSA Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis $26.12 +0.21 (+0.81%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$25.23▼$26.5150-Day Range$17.98▼$26.2952-Week Range$14.12▼$27.88Volume410,223 shsAverage Volume429,246 shsMarket Capitalization$1.85 billionP/E Ratio237.48Dividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Kiniksa Pharmaceuticals alerts: Email Address Kiniksa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside22.5% Upside$32.00 Price TargetShort InterestHealthy5.55% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 29 Articles This WeekInsider TradingSelling Shares$4.67 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.10) to $0.39 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.18 out of 5 starsMedical Sector375th out of 936 stocksPharmaceutical Preparations Industry177th out of 436 stocks 2.5 Analyst's Opinion Consensus RatingKiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKiniksa Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Kiniksa Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.55% of the outstanding shares of Kiniksa Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Kiniksa Pharmaceuticals has recently decreased by 13.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKiniksa Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KNSA. Previous Next 3.0 News and Social Media Coverage News SentimentKiniksa Pharmaceuticals has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Kiniksa Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest5 people have searched for KNSA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows3 people have added Kiniksa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,671,729.00 in company stock.Percentage Held by Insiders54.57% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.95% of the stock of Kiniksa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiniksa Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kiniksa Pharmaceuticals are expected to grow in the coming year, from ($0.10) to $0.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals is 237.48, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals is 237.48, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Book Value per Share RatioKiniksa Pharmaceuticals has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kiniksa Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Read More KNSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KNSA Stock News HeadlinesJuly 26 at 7:18 AM | insidertrades.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Insider Sells 22,000 Shares of StockJuly 26 at 6:22 AM | insidertrades.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sells 136,124 Shares of StockJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 25 at 6:58 AM | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Reaches New 52-Week High After Earnings BeatJuly 25 at 5:38 AM | seekingalpha.comKiniksa Pharmaceuticals International, plc (KNSA) Q2 2024 Earnings Call TranscriptJuly 24 at 2:30 PM | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Releases Earnings Results, Beats Estimates By $0.03 EPSJuly 24 at 12:56 PM | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Increased to $34.00 by Analysts at WedbushJuly 24 at 11:49 AM | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPSJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 24 at 10:43 AM | markets.businessinsider.comBuy Rating for Kiniksa Pharmaceuticals Amidst Strong Arcalyst Performance and Promising Clinical TrialsJuly 24 at 10:43 AM | seekingalpha.comKiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 BeatJuly 24 at 10:43 AM | msn.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2024 Earnings Call TranscriptJuly 23 at 1:31 PM | marketwatch.comKiniksa Pharma Shares Rise 27% After 2Q Earnings, Arcalyst Sales Guidance IncreaseJuly 23 at 9:35 AM | seekingalpha.comKiniksa Pharmaceuticals International, plc 2024 Q2 - Results - Earnings Call PresentationJuly 23 at 7:30 AM | globenewswire.comKiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio ExecutionJuly 22, 2024 | americanbankingnews.comKiniksa Pharmaceuticals (KNSA) to Release Earnings on TuesdayJuly 16, 2024 | globenewswire.comKiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024July 9, 2024 | globenewswire.comKiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren's DiseaseSee More Headlines Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/23/2024Today7/26/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KNSA CUSIPN/A CIK1730430 Webwww.kiniksa.com Phone(781) 431-9100FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$32.00 High Stock Price Target$34.00 Low Stock Price Target$30.00 Potential Upside/Downside+22.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio237.48 Forward P/E RatioN/A P/E GrowthN/ANet Income$14.08 million Net Margins-3.10% Pretax Margin-7.15% Return on Equity-7.83% Return on Assets-6.53% Debt Debt-to-Equity RatioN/A Current Ratio4.21 Quick Ratio3.79 Sales & Book Value Annual Sales$270.26 million Price / Sales6.86 Cash FlowN/A Price / Cash FlowN/A Book Value$6.23 per share Price / Book4.19Miscellaneous Outstanding Shares70,940,000Free Float32,228,000Market Cap$1.85 billion OptionableOptionable Beta0.38 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Sanj K. Patel (Age 55)CEO & Chairman of the Board Comp: $1.57MMr. Eben Tessari (Age 42)Senior VP & COO Comp: $733.29kDr. John F. Paolini FACC (Age 59)M.D., Ph.D., Senior VP & Chief Medical Officer Comp: $855.79kMr. Mark Ragosa C.F.A. (Age 50)Senior VP & CFO Mr. Michael R. Megna CPA (Age 53)Chief Accounting Officer & Group VP of Finance Mr. Chad MorinSenior VP & Chief Compliance OfficerMs. Madelyn Demsky Zeylikman (Age 50)SVP, General Counsel & Secretary More ExecutivesKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNOcular TherapeutixNASDAQ:OCULArcutis BiotherapeuticsNASDAQ:ARQTInnovivaNASDAQ:INVAPliant TherapeuticsNASDAQ:PLRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 2,563 shares on 7/26/2024Ownership: 0.162%Allspring Global Investments Holdings LLCBought 3,837 shares on 7/26/2024Ownership: 0.092%Sanj K PatelSold 136,124 sharesTotal: $3.49 M ($25.65/share)John F PaoliniSold 22,000 sharesTotal: $579,040.00 ($26.32/share)Mark RagosaSold 24,248 sharesTotal: $601,107.92 ($24.79/share)View All Insider TransactionsView All Institutional Transactions KNSA Stock Analysis - Frequently Asked Questions How have KNSA shares performed this year? Kiniksa Pharmaceuticals' stock was trading at $17.54 on January 1st, 2024. Since then, KNSA shares have increased by 48.9% and is now trading at $26.12. View the best growth stocks for 2024 here. How were Kiniksa Pharmaceuticals' earnings last quarter? Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) issued its earnings results on Tuesday, July, 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.03. The firm's revenue for the quarter was up 51.5% compared to the same quarter last year. What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO? 1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Kiniksa Pharmaceuticals IPO? Kiniksa Pharmaceuticals (KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Kiniksa Pharmaceuticals' major shareholders? Top institutional investors of Kiniksa Pharmaceuticals include Hennion & Walsh Asset Management Inc. (0.26%), Linden Thomas Advisory Services LLC (0.17%), Bank of New York Mellon Corp (0.16%) and SG Americas Securities LLC (0.10%). Insiders that own company stock include Sanj K Patel, John F Paolini, Mark Ragosa, Michael R Megna and Barry D Quart. View institutional ownership trends. How do I buy shares of Kiniksa Pharmaceuticals? Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kiniksa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and AbbVie (ABBV). This page (NASDAQ:KNSA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
